Sunday, November 10, 2019
- 2:30PM-4:00PM
-
Abstract Number: 860
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
3S081: SLE – Clinical I: Clinical Trials (857–862)- 2:30PM-4:00PM
-
Abstract Number: 841
Elevation of Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Onset and Risks for Developing Chronic Obstructive Pulmonary Disease or Asthma
3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)- 2:30PM-4:00PM
-
Abstract Number: 817
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
3S079: RA – Etiology & Pathogenesis I (815–820)- 2:30PM-4:00PM
-
Abstract Number: 879
Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study
3S092: New Approaches to Old Diseases (875–879)- 2:30PM-4:00PM
-
Abstract Number: 866
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)- 2:30PM-4:00PM
-
Abstract Number: 815
Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
3S079: RA – Etiology & Pathogenesis I (815–820)- 2:30PM-4:00PM
-
Abstract Number: 862
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
3S081: SLE – Clinical I: Clinical Trials (857–862)- 2:30PM-4:00PM
-
Abstract Number: 872
Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry
3S085: Vasculitis – ANCA-Associated I (869–874)- 2:30PM-4:00PM
-
Abstract Number: 835
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)- 2:30PM-4:00PM
-
Abstract Number: 843
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)- 2:30PM-4:00PM
-
Abstract Number: 852
Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients
3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)- 2:30PM-4:00PM
-
Abstract Number: 826
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)- 2:30PM-4:00PM
-
Abstract Number: 844
Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial
3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)- 2:30PM-4:00PM
-
Abstract Number: 834
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges